HM Payson & Co’s ImmuCell ICCC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $40.2K | Hold |
4,000
| – | – | ﹤0.01% | 753 |
|
|
2026
Q1 | $25.3K | Hold |
4,000
| – | – | ﹤0.01% | 811 |
|
|
2025
Q4 | $24.6K | Hold |
4,000
| – | – | ﹤0.01% | 805 |
|
|
2025
Q3 | $25.9K | Hold |
4,000
| – | – | ﹤0.01% | 797 |
|
|
2025
Q2 | $27.8K | Hold |
4,000
| – | – | ﹤0.01% | 744 |
|
|
2025
Q1 | $19.2K | Hold |
4,000
| – | – | ﹤0.01% | 796 |
|
|
2024
Q4 | $20.6K | Hold |
4,000
| – | – | ﹤0.01% | 768 |
|
|
2024
Q3 | $14.5K | Sell |
4,000
-2,000
| -33% | -$7.78K | ﹤0.01% | 806 |
|
|
2024
Q2 | $29.1K | Hold |
6,000
| – | – | ﹤0.01% | 692 |
|
|
2024
Q1 | $31.8K | Hold |
6,000
| – | – | ﹤0.01% | 675 |
|
|
2023
Q4 | $30.3K | Hold |
6,000
| – | – | ﹤0.01% | 674 |
|
|
2023
Q3 | $31K | Sell |
6,000
-6,130
| -51% | -$31.1K | ﹤0.01% | 662 |
|
|
2023
Q2 | $61.9K | Buy |
12,130
+4,000
| +49% | +$20.5K | ﹤0.01% | 548 |
|
|
2023
Q1 | $41.9K | Hold |
8,130
| – | – | ﹤0.01% | 606 |
|
|
2022
Q4 | $49.8K | Hold |
8,130
| – | – | ﹤0.01% | 551 |
|
|
2022
Q3 | $61K | Hold |
8,130
| – | – | ﹤0.01% | 545 |
|
|
2022
Q2 | $71K | Hold |
8,130
| – | – | ﹤0.01% | 524 |
|
|
2022
Q1 | $78K | Hold |
8,130
| – | – | ﹤0.01% | 533 |
|
|
2021
Q4 | $65K | Buy |
8,130
+6,130
| +307% | +$54.8K | ﹤0.01% | 569 |
|
|
2021
Q3 | $18K | Hold |
2,000
| – | – | ﹤0.01% | 756 |
|
|
2021
Q2 | $19K | Hold |
2,000
| – | – | ﹤0.01% | 742 |
|
|
2021
Q1 | $19K | Sell |
2,000
-18,500
| -90% | -$174K | ﹤0.01% | 765 |
|
|
2020
Q4 | $122K | Sell |
20,500
-9,000
| -31% | -$52.4K | ﹤0.01% | 453 |
|
|
2020
Q3 | $160K | Hold |
29,500
| – | – | ﹤0.01% | 393 |
|
|
2020
Q2 | $139K | Buy |
29,500
+4,000
| +16% | +$17.4K | ﹤0.01% | 393 |
|
|
2020
Q1 | $97K | Hold |
25,500
| – | – | ﹤0.01% | 408 |
|
|
2019
Q4 | $131K | Sell |
25,500
-1,000
| -4% | -$5.16K | ﹤0.01% | 440 |
|
|
2019
Q3 | $147K | Sell |
26,500
-2,000
| -7% | -$11.7K | 0.01% | 429 |
|
|
2019
Q2 | $185K | Sell |
28,500
-23,000
| -45% | -$146K | 0.01% | 409 |
|
|
2019
Q1 | $327K | Buy |
+51,500
| New | +$368K | 0.01% | 218 |
|
Other funds holding ICCC
HM Payson & Co's ICCC Position: Q2 2026 in Review
HM Payson & Co held its ImmuCell (ICCC) position steady in Q2 2026 at 4,000 shares worth $40.2K. The position accounts for ﹤0.01% of the portfolio, ranked #753.
HM Payson & Co first reported a position in ICCC in Q1 2019 and has held it in 30 quarters since. The position peaked at $327K in Q1 2019. 3 funds tracked by Wall St. Rank hold ICCC as of Q2 2026.
- HM Payson & Co held 4,000 shares of ImmuCell worth $40.2K as of Q2 2026.
- HM Payson & Co left its ImmuCell share count unchanged in Q2 2026.
- ImmuCell made up ﹤0.01% of HM Payson & Co's portfolio in Q2 2026, its #753 holding.
- HM Payson & Co first reported a position in ImmuCell in Q1 2019 and has held it in 30 quarters since.
- HM Payson & Co's ImmuCell position peaked at $327K in Q1 2019.
- 3 funds tracked by Wall St. Rank held ImmuCell as of Q2 2026.
Based on HM Payson & Co's 13F filing for Q2 2026, filed 17 Jul 2026.